This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=10 http://www.lsis.com/goto/r10/rss 2012-05-21T11:10:10+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=10 Manag Care. |-| Morrow T. |-| Genentech. TMorrow@ManagedCareMag.com text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=10 The high failure rate of late-stage human clinical trials, particularly in oncology, predicates the need for improved translation of preclinical data from mouse tumor models into clinical predictions. Genetically engineered mouse models (GEMM) may fulfill this need, because they mimic spontaneous and autochthonous disease progression. Using oncogenic Kras-driven GEMMs of lung and pancreatic adenocarcinoma, we recently showed that these models can closely phenocopy human therapeutic responses (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=10 CHICAGO, Illinois, May 18, 2012 the Enrollment Metrix Forum is exploring the patient recruitment in emerging markets in a study conducted by KMR Group. The potential for new patient pools that can speed drug development and establish a broader customer base makes emerging markets a high priority across the industry. Participants in the Forum include: Abbott, Amgen, AZ, Bayer, BMS, J&J, Lilly, Merck, Pfizer, Roche/Genentech, Sanofi/Genzyme, Shire, UCB. The study will evaluate trends in the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=10 Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can be used to quantify the response of tumors to vascular targeting agents. Tumor response is frequently assessed using mathematical models that describe the distribution of contrast agents over time as a function of fundamental characteristics of vascular physiology. Generally, mathematical models of biological systems are abstractions that attempt to retain fundamental physiologic characteristics, thereby allowing for multiple (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=10 BOULDER, Colo., May 16, 2012 (BUSINESS WIRE) - Array BioPharma Inc. today announced oral presentations on its two MEK inhibitors, selumetinib (AZD6244) and MEK162 at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, which will held June 1-5, 2012 at McCormick Place in Chicago, Illinois. Array invented selumetinib and MEK162 and subsequently licensed them to AstraZeneca and Novartis, respectively. Three oral presentations at ASCO: Selumetinib Title: Phase II double-blind, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=10 MARTINSRIED, GERMANY and MUNCHEN, GERMANY-(Marketwire - May 17, 2012) - MorphoSys AG / MorphoSys to Present MOR208 Preclinical Combination Therapy Data at ASCO Meeting . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Synergistic Effects Seen with Four Approved Treatment Options Including Rituximab and Ofatumumab MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced promising pre-clinical data on its (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=10 The HER2 oncogene is overexpressed or amplified in 20% of breast cancers. HER2-positive cancer historically portends a poor prognosis, but the HER2-targeted therapy trastuzumab mitigates this otherwise ominous distinction. Nevertheless, some patients suffer disease recurrence despite trastuzumab, and metastatic disease remains largely incurable due to innate and acquired resistance. Thus, understanding trastuzumab resistance remains an unmet medical need. Through RNA interference screening, we (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=10 A combination of the anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibodies pertuzumab (Genentech) and trastuzumab (Herceptin; Genentech) with docetaxel has reduced risk of progression by 38% over treatment with trastuzumab and docetaxel in a study of 808 patients with HER2-positive metastatic breast cancer. |-| Cancer Discov. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=10 Rapid evolution of state-of-the-art proteomic analyses has encompassed development of high-throughput analytical instrumentation and bioinformatic tools. However, recently, there has been a particular emphasis on increasing the throughput of sample preparation, which has become one of the rate-limiting steps in protein characterization workflows. Researchers have been investigating alternative methods to conventional convection oven incubations to try and reduce sample preparation time for (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=10 PURPOSE: Docetaxel (DTX) is a front-line standard of care chemotherapeutic drug for the treatment of breast cancer. Phosphatidylinositol 3-kinases (PI3K) are lipid kinases that regulate breast tumor cell growth, migration and survival. The current study was intended to determine if GDC-0941, an orally bioavailable class I selective PI3K inhibitor, enhances the anti-tumor activity of DTX in human breast cancer models in vitro and in vivo.EXPERIMENTAL DESIGN: A panel of 25 breast tumor cell (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=10 SOUTH SAN FRANCISCO, Calif. May 15, 2012 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company will present important new data from studies of several of its cancer medicines at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1 to 5, 2012, in Chicago. At the meeting, data on Genentech s late-stage investigational and approved cancer medicines will be communicated in sessions that include 30 oral presentations. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=10 Roche Holding AG's Genentech unit has won the right to try its experimental Alzheimer's drug crenezumab on people with no signs of dementia - the first such trial to gauge whether early intervention can help prevent or slow the disease. The drug will be tested among members of an extended family of about 5,000 people from the Antioquia region of Colombia. They carry a gene that causes them to develop Alzheimer's early, with some experiencing symptoms of memory loss in their mid-30s, scientists (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=10 The homotrimeric human serine protease HtrA1 is homologous to bacterial HtrA proteases regarding the trypsin-like catalytic and PDZ domains but differs by the presence of an N-terminal domain with IGFBP and Kazal homology. The crystal structures and SAXS analysis presented herein reveal the rare tandem of IGFBP- and Kazal-like modules, a protease active site that adopts a competent conformation in the absence of substrate or inhibitor and a model for the intact protein in solution. Highly (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=10 Preeclampsia (gestational proteinuric hypertension) complicates 5% to 8% of all pregnancies, and is a major cause of maternal and perinatal morbidity and mortality. It is a multisystem disorder specific to human pregnancy and the puerperium. Although the etiology is unknown, increasing evidence from both animal and human studies suggests that an imbalance in circulating pro-(vascular endothelial growth factor [VEGF], placental growth factor) and anti-angiogenic factors (soluble fms-like (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=10 BOULDER, Colo.-(BUSINESS WIRE)-Array BioPharma Inc. (NASDAQ: ARRY) announced today that the strategic alliance between Array and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has been honored with the Breakthrough Alliance Award of 2012. The award, sponsored by Deloitte Recap, was presented at the Allicense 2012 Conference in San Francisco. Annually, the Allicense Conference nominates five biotech-pharmaceutical alliances as the breakthrough deals of the previous year. (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=10 United States Patent: 8178082 |-| Title: Methods for up-regulating PAP1 in animals suffering from pancreatic disorders |-| Inventors: Gurney; Austin L. (Belmont, CA), Aggarwal; Sudeepta (San Bruno, CA), Xie; Ming-Hong (San Francisco, CA), Maruoka; Ellen M. (San Francisco, CA), Foster; Jessica S. (Hayward, CA), Goddard; Audrey (San Francisco, CA), Wood; William I. (Hillsborough, CA) |-| Assignee: Genentech, Inc. (South San Francisco, CA) |-| The present invention is directed to interleukin-22 (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=10 United States Patent: 8178107 |-| Title: Method of treatment of thrombocytopenia or risk thereof using MPL ligand (thrombopoietin), variants, and fragments thereof |-| Inventors: Eaton; Dan L. (San Rafael, CA), De Sauvage; Frederic J. (Foster City, CA) |-| Assignee: Genentech, Inc. (South San Francisco, CA) |-| Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=10 NEW YORK, NY-(Marketwire - May 14, 2012) - Highlighted Links www.ohrpharmaceutical.com Ohr Pharmaceutical Inc. (OTCBB: OHRP) announced today that its Squalamine Eye Drops, a potent inhibitor of multiple growth factors implicated in angiogenesis, has been awarded Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of the wet form of macular degeneration (wet-AMD). "We believe the Fast Track designation underscores the importance of developing an (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=10 Constitutive NF-?B (nuclear factor ?B) activation in B-cell lymphomas relies greatly on the CARMA1 [CARD (caspase recruitment domain)-containing MAGUK (membrane-associated guanylate kinase) 1]-Bcl10-MALT1 (mucosa-associated lymphoid tissue translocation gene 1) signalling complex. Within this protein complex, MALT1 possesses a rather unique enzymatic activity, which allows it to cleave Bcl10, RelB and CYLD, among other substrates. The catalytic activity of MALT1 promotes activation of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=10 Sensitive detection of protein interactions is a critical step toward understanding complex cellular processes. As an alternative to fluorescence-based detection, Renilla reniformis luciferase conjugated to quantum dots results in self-illuminating bioluminescence resonance energy transfer quantum dot (BRET-Qdot) nanoprobes that emit red to near-infrared bioluminescence light. Here, we report the development of an ultrasensitive technology based on BRET-Qdot conjugates modified with (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=10 We report on the significant improvement of central macular thickness in a case of clinically significant macular edema after dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex; Allergan, Inc, Irvine, CA, USA). Patient presented to us with persistent clinically significant macular edema (CSME) in both eyes. Right eye received dexamethasone implant and left eye received two intravitreal bevacizumab injections 1.25 mg/0.05 mL (Avastin; Genentech Inc., South San Francisco, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=10 To identify new genes important in fat metabolism we utilized the Lexicon-Genentech knockout database of genes encoding transmembrane and secreted factors and whole murine genome transcriptional profiling data we generated for 3T3-L1 in vitro adipogenesis. Cross-referencing null models evidencing metabolic phenotypes with genes induced in adipogenesis led to identification of a new gene which we name herein RIFL (Refeeding Induced Fat and Liver). RIFL null mice have serum triglyceride levels (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=10 The PTEN/PI3K pathway is commonly mutated in cancer and therefore represents an attractive target for therapeutic intervention. To investigate the primary phenotypes mediated by increased pathway signaling in a clean, patient-relevant context, an activating PIK3CA mutation (H1047R) was knocked-in to an endogenous allele of the MCF10A non-tumorigenic human breast epithelial cell line. Introduction of an endogenously mutated PIK3CA allele resulted in a marked epithelial-mesenchymal transition (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=10 The protein serine-threonine kinase Akt undergoes a substantial conformational change upon activation, which is induced by the phosphorylation of two critical regulatory residues, threonine 308 and serine 473. Paradoxically, treating cells with adenosine 5'-triphosphate (ATP)-competitive inhibitors of Akt results in increased phosphorylation of both residues. We show that binding of ATP-competitive inhibitors stabilized a conformation in which both phosphorylated sites were inaccessible to (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=10 It is well recognized that poor dissolution rate and solubility of drug candidates are key limiting factors for oral bioavailability. While numerous technologies have been developed to enhance solubility of the drug candidates, poor water solubility continuously remains a challenge for drug delivery. Among those technologies, amorphous solid dispersions (SD) have been successfully employed to enhance both dissolution rate and solubility of poorly water-soluble drugs. This research reports a (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=10 PURPOSEThe AVAGAST study showed that adding bevacizumab to chemotherapy in patients with advanced gastric cancer improves progression-free survival and tumor response rate but not overall survival. To examine the hypothesis that angiogenic markers may have predictive value for bevacizumab efficacy in gastric cancer, AVAGAST included a prospective, mandatory biomarker program. PATIENTS AND METHODSPatients with previously untreated, locally advanced or metastatic gastric cancer were randomly (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=10 Attempts to express eukaryotic multi-spanning membrane proteins at high-levels have been generally unsuccessful. In order to investigate the cause of this limitation and gain insight into the rate limiting processes involved, we have analyzed the effect of translation levels on the expression of several human membrane proteins in Escherichia coli (E. coli). These results demonstrate that excessive translation initiation rates of membrane proteins cause a block in protein synthesis and (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 This is a Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter study enrolling patients with active rheumatoid arthritis (RA). |-| A Phase II, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis |-| Genentech |-| Show 55 Study Locations text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 Diabetic premacular hemorrhage occurs when blood from preretinal neovascular tissue is entrapped between the retina and the posterior hyaloid in the macular area. It may occur spontaneously or secondary to traction from a localized posterior vitreous detachment. This complication may greatly disturb the central vision and may be an important stimulant of fibrovascular proliferation. Bevacizumab (Avastin, Genentech, Inc.) is a humanized monoclonal antibody against vascular endothelial growth (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 Primary objective - to determine the 6-month progression free survival (PFS) of adult patients with recurrent glioblastoma multiforme/gliosarcoma treated with bi-weekly temozolomide plus (Avastin) bevacizumab. Secondary objectives - to determine radiographic response including specialized MRI sequences, safety and overall survival of adult patients with with recurrent glioblastoma multiforme/gliosarcoma treated with bi-weekly temozolomide plus bevacizumab (Avastin). Additionally, tumor DNA (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 The purpose of this study is to determine the safety and effectiveness of a combination of chemotherapy, capecitabine and oxaliplatin, plus the antibodies bevacizumab and trastuzumab. Trastuzumab (also called Herceptin) is an antibody that attacks HER2 protein in tumor cells. Bevacizumab (also called Avastin) works by slowing or stopping the growth of cells in cancer tumors by decreasing the blood supply of the tumors. If blood supply is decreased, oxygen and nutrients that are needed for (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 This trial will evaluate the clinical significance of the PRO Onc assay and will assess the efficacy of HER2-targeted therapy in patients with HER2-negative breast cancer who have been identified as having HER2 overexpression/activation by the PRO Onc Assay. |-| Use of the PRO Onc Assay to Assess HER2 Amplification and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing |-| Sarah Cannon Research Institute, Prometheus Therapeutics and (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 This is an open-label, Phase I/II study of intravitreally administered ranibizumab either 0.5-mg and/or 2.0-mg in subjects with clinical, angiographic, and ocular coherence tomography (OCT) evidence of diabetic retinopathy with associated diabetic macular edema following bevacizumab therapy. Thirty patients will be enrolled in this study. Consented, enrolled subjects will receive multiple open-label intravitreal injections of 0.5 mg ranibizumab administered every 30 days (7 days) for 3 (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 Eosinophilic Esophagitis(EoE) is a condition characterized commonly by vomiting, nausea, epigastric pain, dysphagia, heartburn and food impaction among other gastrointestinal symptoms along with obstructive esophageal symptoms in both pediatric and adult population. The pathology of this disease is postulated to be allergy mediated and the incidence of this disease is seen to parallel an increase in the incidence of allergies and asthma. Most of the current therapies for EoE are directed at (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 This study is to determine the feasibility of administering neoadjuvant carboplatin, paclitaxel, and bevacizumab without excessive dose modification or cycle delay in patients with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. |-| Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer |-| Columbia University, Genentech |-| United States, New York Columbia University Medical (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 The aim of the study is to find out if Rituximab, which is an antibody against specific white cells involved in rejection, when combined with standard anti-rejection treatment can more effectively reverse the rejection process. Our hypothesis is that with acute rejection there is activation of B cells and the subsequent development of anti-donor antibodies that ultimately lead to graft loss. More effective therapy targeted at B cells may abort the development of anti-HLA antibodies, prevent (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 This is a phase IV, multi-center, open label, case-controlled, observational study evaluating prepubertal, rhGH-naive subjects who receive daily doses of rhGH with the NuSpin device. |-| A Phase IV, Open Label, Multicenter, Case-controlled Study of Growth in Patients Using the Nutropin AQ Nuspin |-| Genentech |-| United States, California Investigational Site Sacramento, California, United States, 95819 Investigational Site San Diego, California, United States, 92123 United States, Colorado (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 This is a multicenter, single-arm, open-label Phase II study to evaluate the activity of GDC-0980 in patients with recurrent or persistent endometrial cancer. The safety, tolerability, and pharmacokinetics of GDC-0980 will also be evaluated. |-| A Phase II Evaluation of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma |-| Genentech |-| Show 26 Study Locations text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 This is an open-label, multicenter, Phase Ib dose-escalation study designed to assess the safety, tolerability and pharmacokinetics of oral dosing of GDC-0973 and GDC-0941 administered in combination in patients with solid tumors. |-| A Phase Ib, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors |-| Genentech |-| United States, (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 The purpose of this study is to test the effectiveness of a drug called erlotinib in treating the tumor. The study drug, erlotinib (also called Tarceva) is a pill (taken by mouth) that has been approved by the U.S. Food and Drug Administration (FDA) for the patients with other cancers (lung cancer or pancreatic cancer). It is considered investigational in brain tumors. Erlotinib blocks a messenger that tells cancer cells to grow. That messenger is called epidermal growth factor receptor which (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 The purpose of this study is to perform exploratory analyses to evaluate rates of functional and structural change in glaucoma, to identify predictors of rapid progression in patients with glaucoma and to identify possible genetic factors and biomarkers associated with the disease. |-| STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk (STARFISH) |-| University of California, San Diego, Genentech |-| United States, California (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 This is a Phase II, open-label, single arm, single-stage, multi-center trial in patients with relapsed NSCLC, with the objective of assessing the activity of the combination of erlotinib and pertuzumab on the basis of the endpoint of FDG-PET response rate (RR). |-| An Open-Label Phase II Multicenter Study of the Safety and Activity (As Measured by FDG PET Imaging Changes) of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-Small Cell Lung Cancer |-| Genentech, Roche (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 The goal of this clinical research study is to learn if Tarceva (erlotinib hydrochloride; OSI-774) can help to shrink the tumor or slow its growth, before surgery, in patients with transitional cell carcinoma. |-| A Phase II Exploratory Study of Pre-Operative Treatment With Erlotinib (Tarceva) in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy |-| M.D. Anderson Cancer Center, Genentech |-| United States, Texas UT MD Anderson Cancer Center Houston, Texas, United (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 This is an open-label, multicenter, Phase I dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0623 in patients with locally advanced or metastatic solid tumors. Patients will be enrolled in one of two stages: a dose-escalation stage (Stage I) followed by an expansion stage (Stage II). Stage I will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of GDC-0623 administered orally on a 21 day on/7-day off dosing schedule. |-| An (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 This randomized, multicenter, two-arm, open-label study (TH3RESA) will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) in comparison with treatment of the physician's choice in patients with metastatic or unresectable locally advanced/recurrent HER2-positive breast cancer. Eligible patients will be randomized to receive either T-DM1 3.6 mg/kg intravenously every 21 days or treatment of the physician's choice. Anticipated time on study treatment is until disease progression or (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 The rationale for this multicenter, phase II trial is to examine the impact of carboplatin/paclitaxel with bevacizumab in the preoperative treatment of patients with stage IB ( 4.0 cm), II, and select stage III NSCLC. If this novel regimen proves to be safe and active in this setting, this would provide rationale for further investigation in a larger, prospective, randomized setting. |-| Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (4 cm), II, or Select (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 Hypotheses: The provision of thrice weekly subcutaneous (SQ) recombinant growth hormone (rGH) therapy to children receiving in-center hemodialysis (HD) will result in improved growth. The provision of thrice weekly SQ rGH therapy to children receiving in-center HD will result in improved lean body mass, nutritional status and quality of life. TIW rGH treatment regimen (0.35 mg/kg/week divided into 3 doses, each dose being given at the conclusion of the dialysis treatment) for up to 2 years; (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 This is an open-label, multicenter, single-agent, phase II study of continuous oral Zelboraf (vemurafenib) in patients with locally-advanced, unresectable, stage IIIc or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. |-| An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E |-| Genentech |-| United (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 Rituximab will be tested for its safety and potential efficacy in treating B cell dense renal allograft rejection episodes in children receiving renal transplants at Stanford University |-| A Prospective Open-Labeled Randomized Study of Rituximab Versus Standard of Care, for Treatment of Acute Allograft Rejection in Pediatric Renal Transplantation |-| Stanford University, Genentech and Biogen IDEC |-| United States, California Stanford University School of Medicine Stanford, California, United (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=10 The purpose of this research study is to assess the efficacy of antiangiogenic therapy (bevacizumab) and androgen deprivation versus androgen deprivation alone at the time of minimal systemic disease (based on rising PSA without metastases). |-| Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy |-| Dana-Farber Cancer Institute, Genentech, Beth Israel Deaconess Medical Center, Brigham and (…)